Edition:
United Kingdom

People: Akebia Therapeutics Inc (AKBA.OQ)

AKBA.OQ on NASDAQ Stock Exchange Global Market

4.83USD
9:00pm BST
Change (% chg)

$0.13 (+2.77%)
Prev Close
$4.70
Open
$4.79
Day's High
$4.94
Day's Low
$4.71
Volume
342,128
Avg. Vol
357,612
52-wk High
$10.44
52-wk Low
$3.51

Hadas, Nicole 

Ms. Nicole R. Hadas serves as Senior Vice President, Chief Legal Officer and Secretary of the Company. She joined Akebia in 2013 and is Senior Vice President, Chief Legal Officer and Secretary. Prior to joining Akebia, Ms. Hadas was Vice President and General Counsel at OvaScience, Inc. in 2013. Previously, Ms. Hadas served as Senior Vice President and General Counsel at Inspiration Biopharmaceuticals, Inc., a company that filed for protection under Chapter 11 of the U.S. Bankruptcy Code in October 2012 prior to the successful sale of its hemophilia assets to Cangene Corporation and Baxter International in early 2013 for a total aggregate consideration that could exceed $1 billion. From 2001 to 2011, Ms. Hadas worked at Genzyme Corporation, now Sanofi Genzyme, most recently as Senior Corporate Counsel. Prior to Genzyme, she was an associate at Foley Hoag representing biopharmaceutical companies and healthcare providers in a wide variety of matters. Ms. Hadas received a B.A. from the University of Michigan and a J.D. from Boston College Law School.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Adrian Adams

133,436

John Butler

3,471,070

Jason Amello

1,091,020

Nicole Hadas

--

Steven Burke

--

Michel Dahan

1,276,790
As Of  31 Dec 2018